- Conditions
- Eczema, Atopic Dermatitis
- Interventions
- Amlitelimab, Placebo
- Drug
- Lead sponsor
- Kymab Limited
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 20
- States / cities
- Fremont, California • Sacramento, California • Boca Raton, Florida + 16 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1729–1752
of 10,850
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cystic Fibrosis, Abdominal Pain, Helicobacter Pylori Infection
- Interventions
- Not listed
- Lead sponsor
- Penn State University
- Other
- Eligibility
- 5 Years to 18 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Hemophagocytic Lymphohistiocytosis, X-Linked Lymphoproliferative Disorders, Chediak-Higashi Syndrome, Griscelli Syndrome, Immunologic Deficiency Syndromes, Langerhans-Cell Histiocytosis
- Interventions
- Stem Cell Transplant, Fludarabine, Melphalan, Anti-thymocyte globulin (ATG), Campath 1H, Cyclosporin A, Mycophenolate mofetil, Intravenous immunoglobulin (IVIG)
- Procedure · Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 35 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2014
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Neonatal Encephalopathy
- Interventions
- Not listed
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 6 Years to 8 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Hereditary Hemorrhagic Telangiectasia, Arteriovenous Malformations, Telangiectasia, Epistaxis, GastroIntestinal Bleeding, Cerebral Arteriovenous Malformations, Vascular Malformation
- Interventions
- Not listed
- Lead sponsor
- Cure HHT
- Other
- Eligibility
- Not listed
- Enrollment
- 10,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2033
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more
- Conditions
- Hemophilia B
- Interventions
- rFIX
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2005
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Aurora, Colorado • Detroit, Michigan + 4 more
- Conditions
- Cystic Fibrosis
- Interventions
- Spiro PD personal spirometer
- Device
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 10 Years to 21 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Atopic Dermatitis
- Interventions
- Fluocinonide
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Spinal Fusion
- Interventions
- NanoBone Bone Graft Substitute
- Other
- Lead sponsor
- Artoss Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 330 participants
- Timeline
- 2020 – 2025
- U.S. locations
- 6
- States / cities
- Chandler, Arizona • Tempe, Arizona • San Diego, California + 3 more
- Conditions
- Fragile X Syndrome
- Interventions
- Metformin, Placebo oral tablet
- Drug
- Lead sponsor
- Rowan University
- Other
- Eligibility
- 18 Years to 50 Years · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Stratford, New Jersey
- Conditions
- Atopic Dermatitis
- Interventions
- EpiCeram Skin Barrier Emulsion, Desonide Cream 0.05%
- Device · Drug
- Lead sponsor
- Promius Pharma, LLC
- Industry
- Eligibility
- 3 Months to 12 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 5
- States / cities
- Denver, Colorado • Chicago, Illinois • Winston-Salem, North Carolina + 2 more
- Conditions
- Hemoglobinopathies
- Interventions
- Not listed
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Not listed
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2035
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Osteoporosis, Cerebral Palsy, Spina Bifida, Osteopenia, Osteogenesis Imperfecta
- Interventions
- pamidronate, saline
- Drug · Other
- Lead sponsor
- University of New Mexico
- Other
- Eligibility
- 4 Years to 18 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Atopic Dermatitis
- Interventions
- Crisaborole 2%, Vehicle
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 3 Months and older
- Enrollment
- 620 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 25
- States / cities
- Fountain Valley, California • Fremont, California • Colorado Springs, Colorado + 20 more
- Conditions
- Atopic Dermatitis, Atopic Hand Eczema
- Interventions
- Tralokinumab, Placebo
- Drug
- Lead sponsor
- LEO Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 235 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Fort Smith, Arkansas • Fountain Valley, California + 19 more
- Conditions
- Sickle Cell Disease
- Interventions
- I-STRONG, Enhanced Usual Care (EUC)
- Behavioral · Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- Hartford, Connecticut • Atlanta, Georgia • Cincinnati, Ohio
- Conditions
- Iron Overload
- Interventions
- deferiprone
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
- Interventions
- Not listed
- Lead sponsor
- American Thrombosis and Hemostasis Network
- Network
- Eligibility
- Not listed
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2035
- U.S. locations
- 76
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 60 more
- Conditions
- Sickle Cell Disease
- Interventions
- Rilzabrutinib, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 10 Years to 65 Years
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Clovis, California + 17 more
- Conditions
- Thalassemia
- Interventions
- Busulfan, Fludarabine, Campath 1H, Cyclophosphamide, MESNA
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Up to 64 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cystic Fibrosis
- Interventions
- LUM/IVA
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 2 Years to 5 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 17
- States / cities
- Palo Alto, California • Aurora, Colorado • Chicago, Illinois + 14 more
- Conditions
- Down Syndrome, Alzheimer Disease
- Interventions
- Vitamin E, multivitamin, Placebo
- Drug
- Lead sponsor
- New York State Institute for Basic Research
- Government
- Eligibility
- 50 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2012
- U.S. locations
- 14
- States / cities
- Farmington, Connecticut • Tampa, Florida • Atlanta, Georgia + 10 more
- Conditions
- Graft Versus Host Disease, Hyperkalemia, Craniectomy, Synostectomy, FOA, Congenital Malformations
- Interventions
- Irradiated Blood Transfusions, Non-Irradiated Blood Transfusions
- Other
- Lead sponsor
- Valley Anesthesiology Consultants
- Other
- Eligibility
- 2 Months to 6 Months
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Cystic Fibrosis, Pancreatic Insufficiency, Abnormal Glucose Tolerance, Diabetes
- Interventions
- Dulaglutide 0.75Mg/0.5Ml Inj Pen
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Philadelphia, Pennsylvania